WC
ADPT icon

Wexford Capital’s Adaptive Biotechnologies ADPT Stock Holding History

Wexford Capital’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,197
Closed -$83.2K – 241
2025
Q1 		$83.2K Buy
+11,197
New +$86.1K 0.02% 206

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wexford Capital's ADPT Position: Q2 2025 in Review

Wexford Capital sold out of Adaptive Biotechnologies (ADPT) in Q2 2025, closing a stake of 11,197 shares — an estimated $83.2K sold.

Wexford Capital first reported a position in ADPT in Q1 2025 and held it in 1 quarter. The position peaked at $83.2K in Q1 2025. 242 funds tracked by Wall St. Rank hold ADPT as of Q2 2025.

  • Wexford Capital reported no remaining Adaptive Biotechnologies position as of Q2 2025 after selling out during the quarter.
  • Wexford Capital sold 11,197 Adaptive Biotechnologies shares in Q2 2025, an estimated $83.2K.
  • Wexford Capital first reported a position in Adaptive Biotechnologies in Q1 2025 and held it in 1 quarter.
  • Wexford Capital's Adaptive Biotechnologies position peaked at $83.2K in Q1 2025.
  • 242 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2025.

Based on Wexford Capital's 13F filing for Q2 2025, filed 14 Aug 2025.